In Mice Engineered to Keep Anandamide Around, THC Drove More Tolerance and Withdrawal

Male FAAH knockout mice, which have impaired breakdown of anandamide, received subchronic dosing with either anandamide or THC at equi-active, maximally effective doses. Tolerance was quantified as rightward shifts in dose–effect curves for antinociception, catalepsy, and hypothermia. CB1 receptor function and density were assessed using agonist-stimulated [35S]GTPγS binding in brain and spinal cord and [3H]WIN55,212-2 binding in brain. Dependence was probed by precipitating withdrawal with the CB1 antagonist rimonabant after repeated dosing. Cross-tolerance experiments compared how prior exposure altered responses to each ligand. The abstract does not report sample size, dosing route, or exact dosing schedules.

The study separates two ways of engaging the endocannabinoid system in mice. Repeated direct CB1 agonism with THC produced stronger tolerance, more receptor downregulation, and a clearer withdrawal signal. Elevating signaling via an endogenous ligand, anandamide, produced milder adaptations under parallel conditions in a model designed to keep anandamide from being rapidly degraded. For drug development that targets endocannabinoid tone rather than directly pushing the receptor, this mechanistic contrast is central.

Cannabinoid tolerance is often discussed as one thing. This mouse work shows it is not. The extent of behavioral tolerance depends on the ligand’s intrinsic efficacy at CB1 during testing and on how the receptor system adapts to the prior regimen. In these experiments, direct CB1 stimulation by THC pushed the system toward desensitization and downregulation. Sustained enhancement of an endogenous ligand produced a softer footprint on the receptor system in this model. Those differences frame why elevating endocannabinoid tone and administering a CB1 agonist can land in different places, even if both act through the same receptor family.

This is an animal study in a genetically modified model where FAAH is absent. That elevates anandamide and other FAAH substrates in ways that do not mirror typical physiology. Only males were studied. The abstract does not report sample sizes, dosing routes, or exact dosing intervals, which makes it hard to gauge effect sizes and reproducibility. Behavioral outcomes were limited to the classic rodent tetrad, which captures only a slice of cannabinoid effects. Withdrawal was defined by antagonist-precipitated signs, an operational model that may not map onto other dependence measures. Anandamide and THC differ in more than efficacy, including metabolism and signaling kinetics, which could contribute to the adaptation differences.